THERAPEUTIC EFFECT OF CANNABIDIOL (CBD) IN PLAQUE PSORIASIS
Keywords:
endocannabinoid system, psoriasis, cannabidiol, phytocannabinoidsAbstract
The endocannabinoid system (ECS) of the skin is a complex molecular network of receptors, endocannabinoids, and enzymes that has sparked the interest of modern dermatology since its discovery in 1988. Studies have shown that dysregulation of ECS is closely associated with various skin diseases, including psoriasis as one of the most common autoimmune skin diseases. Psoriasis has a bimodal distribution of onset and a massive socioeconomic impact in modern societies, since it affects 3% of the global population. Although our knowledge regarding the association between ECS and psoriasis is limited, modulators of ECS have paved a novel therapeutic approach to be considered when treating psoriasis patients. Cannabidiol (CBD) is a non-psychotic, lipophilic, twenty-one carbon terpenophenolic phytocannabinoid derived from Cannabis plant that has promising therapeutic properties. Topical or transdermal formulations containing CBD have anti-inflammatory properties via inhibition of NF-kB signaling pathway and upregulation of keratin 6 and 16 in psoriasis patients. This review article discusses the up-to-date knowledge of the endocannabinoid system in the skin, its role in the pathophysiology of psoriasis, and therapeutic potential of cannabidiol in treatment of patients with plaque psoriasis.
References
https://www.psoriasis.org/psoriasis-statistics/ (Accessed on 08.01.2025)
Lowe H, Toyang N, Steele B, Bryant J, Ngwa W. The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases. Int J Mol Sci. 2021 Aug 31;22(17):9472. doi:10.3390/ijms22179472.
Yoo EH, Lee JH. Cannabinoids and Their Receptors in Skin Diseases. Int J Mol Sci. 2023 Nov 20;24(22):16523. doi: 10.3390/ijms242216523. PMID: 38003712; PMCID: PMC10672037.
Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006 Jan;147 Suppl 1(Suppl 1):S163-71. doi: 10.1038/sj.bjp.0706406. PMID: 16402100; PMCID: PMC1760722.
Río CD, Millán E, García V, Appendino G, DeMesa J, Muñoz E. The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders. Biochem Pharmacol. 2018 Nov;157:122-133. doi: 10.1016/j.bcp.2018.08.022. Epub 2018 Aug 20. PMID: 30138623.
Castillo-Arellano J, Canseco-Alba A, Cutler SJ, et al. The Polypharmacological Effects of Cannabidiol. Molecules. 2023;28(7):3271. doi: 10.3390/molecules28073271.
Filipiuc SI, Neagu AN, Uritu CM, Tamba BI, Filipiuc LE, Tudorancea IM, Boca AN, Hâncu MF, Porumb V, Bild W. The Skin and Natural Cannabinoids-Topical and Transdermal Applications. Pharmaceuticals. 2023;16(7):1049. doi:10.3390/ph16071049. PMID: 37513960; PMCID: PMC10386449.
Baswan SM, Klosner AE, Glynn K, Rajgopal A, Malik K, Yim S, Stern N. Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders. Clin Cosmet Investig Dermatol. 2020;13:927-942. doi: 10.2147/CCID.S286411.
Martinez Naya N, Kelly J, Corna G, Golino M, Abbate A, Toldo S. Molecular and Cellular Mechanisms of Action of Cannabidiol. Molecules. 2023 Aug 9;28(16):5980. doi: 10.3390/molecules28165980.
Legare CA, Raup-Konsavage WM, Vrana KE. Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals. Pharmacology. 2022;107(3-4):131-149. doi: 10.1159/000521683. Epub 2022 Jan 28.
Di Meo C, Tortolani D, Standoli S, Ciaramellano F, Angelucci BC, Tisi A, Kadhim S, Hsu E, Rapino C, Maccarrone M. Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes. Biofactors. 2025;51(1):e2122. doi:10.1002/biof.2122.
